Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. develops clinical-stage therapeutics that modulate lipid-signaling pathways, including programs tied to the endocannabinoid system and fatty acid-binding proteins. Company news commonly covers pipeline updates for ART27.13 and ART26.12, including cancer anorexia-cachexia, neuropathic pain, glaucoma, dermatologic, neurological and other inflammation-related indications.
Recurring developments include FABP5 inhibitor research, peer-reviewed publications, collaborations using biological-data analysis, preclinical and clinical program disclosures, patent activity, and externally funded studies. Artelo news also includes capital-structure actions such as private placements, common stock and warrant offerings, and Nasdaq listing-compliance matters.
Artelo Biosciences (Nasdaq: ARTL) reported that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering the intended commercial formulation of ART27.13, its peripherally selective cannabinoid agonist. The allowed claims cover compositions of ART27.13 dispersed in polyethylene glycol and are expected to extend patent protection for ART27.13 in the United States through 2041, supporting the company’s long-term intellectual property strategy.
ART27.13 is in two Phase 2 studies: the CAReS trial for cancer-related anorexia and the DREAM study in glaucoma or ocular hypertension. According to Artelo Biosciences, Phase 1 data showed good tolerability and early signs of stabilizing or reversing weight loss in over 60% of participants, while interim Phase 2 CAReS results showed reversal of cancer-related anorexia in all patients on the highest dose, with placebo patients continuing to lose weight. The DREAM Phase 2 study, funded by Glaucoma UK and the HSC R&D Division, is assessing once-daily oral ART27.13 to reduce intraocular pressure, with initial results anticipated in the fourth quarter of this year.
Artelo Biosciences (Nasdaq: ARTL) reported second quarter 2026 results and pipeline progress. The company is preparing a Phase 1 multiple ascending dose study of ART26.12 in Q4 2026 after favorable first-in-human safety, pharmacokinetics, and metabolite profiling data supporting chronic pain development.
ART27.13 showed encouraging interim Phase 2 CAReS outcomes in body weight, lean mass and activity, plus nonclinical neuropathy pain data, alongside a fully funded Phase 2 glaucoma study. ART12.11 advanced preclinical work, supported by a CBD literature review. Artelo completed an $11.0 million financing. Q2 2026 R&D was $0.9 million, G&A $1.6 million, net loss $2.4 million, with $4.2 million in cash and investments as of June 30, 2026.
Artelo Biosciences (Nasdaq: ARTL) reported that the first patient has been dosed in the Phase 2 DREAM study, which is evaluating its orally administered synthetic cannabinoid ART27.13 in patients with glaucoma or ocular hypertension. ART27.13 is described as a peripherally selective cannabinoid receptor agonist intended to modulate intraocular pressure (IOP) via receptors in ocular tissues.
The investigator-led study is funded by Glaucoma UK and the HSC R&D Division, sponsored by the Belfast Health and Social Care Trust, and conducted by the Northern Ireland Clinical Trials Unit. It is led by glaucoma specialist Professor Augusto Azuara-Blanco of Queen’s University Belfast. According to Artelo, initial DREAM results are anticipated in Q4 2026, potentially expanding ART27.13’s clinical reach into ophthalmology amid ongoing unmet need for safe, well-tolerated IOP-lowering therapies.
Artelo Biosciences (Nasdaq: ARTL) reported that a peer-reviewed review article, led by an Artelo scientist and now published in the British Journal of Clinical Pharmacology, evaluated over 50 studies of low-dose cannabidiol (CBD) typical of over-the-counter products.
The review found that CBD doses ≤2.5 mg/kg or ≤175 mg/day generally produced little to no evidence of biological or therapeutic effect, with plasma exposures 5–100 times lower than therapeutic epilepsy doses. It also identified significant drug-drug interactions with common medications. According to Artelo, these data highlight formulation and delivery limitations and support the rationale for its proprietary CBD cocrystal, ART12.11, which has shown higher CBD plasma levels in preclinical studies and is being advanced toward clinical development.
Artelo Biosciences (Nasdaq: ARTL) reported new nonclinical data showing its selective FABP5 inhibitor ART26.12 reduced osteoarthritis (OA)-associated pain behaviors after acute and chronic oral dosing over four weeks, with efficacy described as comparable to naproxen, a widely used NSAID in OA.
According to Artelo, ART26.12 produced distinct changes in endocannabinoids and related bioactive lipids versus naproxen, supporting a novel mechanism of action. Animals receiving ART26.12 showed significantly less stomach tissue damage, including non-glandular hyperkeratosis, suggesting potential for an improved gastrointestinal safety profile relative to naproxen in this model.
The company stated that these data expand ART26.12’s potential utility beyond neuropathic pain into OA and broader chronic pain conditions. Preparations are underway for a multiple ascending repeat dose study in healthy volunteers, with enrollment anticipated to begin in the fourth quarter of this year.
Artelo Biosciences (Nasdaq: ARTL) reminded shareholders to vote their shares in advance of its virtual Annual Meeting of Shareholders scheduled for July 17, 2026. The company urges all shareholders of record, regardless of holdings size, to promptly submit proxies using the methods described in previously distributed proxy materials.
According to Artelo Biosciences, every proxy, whether voting FOR, AGAINST, or ABSTAIN on proposals, helps establish the required quorum so the meeting’s business can proceed. Failure to achieve a quorum could force adjournment and reconvening, increasing the company’s expenses and administrative effort.
Artelo Biosciences (Nasdaq: ARTL) reported new nonclinical data showing its peripherally restricted dual cannabinoid receptor agonist ART27.13, currently in Phase 2 development for cancer-related anorexia cachexia syndrome (CACS), reduced neuropathic pain-associated behaviors in a paclitaxel-induced peripheral neuropathy model in both male and female animals.
According to Artelo Biosciences, repeated dosing with ART27.13 decreased mechanical allodynia and thermal hyperalgesia, supporting further evaluation in oncology supportive care. Interim results from the CAReS Phase 2 study in CACS previously showed encouraging trends in body weight, lean body mass, activity levels, and a favorable safety profile at doses up to 1300 µg/day, in an indication with no FDA-approved treatments.
Artelo Biosciences (Nasdaq: ARTL) reported new preclinical data for ART26.12, a selective FABP5 inhibitor in Phase 1 development, in a mouse model of spinal cord injury neuropathic pain.
According to Artelo, FABP5 inhibition reduced mechanical hypersensitivity, decreased spontaneous pain behaviors, suppressed nociceptor hyperexcitability, and improved pain outcomes after oral dosing.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, reported new multi-omics data on ART26.12, its selective FABP5 inhibitor, at the ICRS 2026 symposium in Dijon, France.
According to Artelo Biosciences, analyses across multiple disease models showed consistent modulation of the pro-inflammatory lipid linoleic acid and related lipid-signaling pathways, suggesting a potential mechanistic link for FABP5 inhibition’s broad therapeutic activity and supporting ongoing Phase 1 development.
Artelo Biosciences (Nasdaq:ARTL) reported Phase 1 first-in-human data for ART26.12, a selective FABP5 inhibitor, at ICRS 2026. Single ascending oral doses in healthy volunteers were generally well-tolerated and showed linear, dose-dependent pharmacokinetics with dose-proportional systemic exposure.
ART26.12 plasma levels exceeded projected therapeutic concentrations from preclinical studies, with a wide margin between anticipated therapeutic exposure and maximum tolerated doses. AI- and machine learning–driven analyses of proteomic and lipidomic data identified treatment-related changes across multiple biological pathways, supporting development of pharmacodynamic biomarkers.
Artelo Biosciences views these clinical and translational findings as important progress for ART26.12 and follow-on FABP5 inhibitors, including potential non-opioid applications in painful neuropathies.